Search

Meet Sandra Lowe, who was diagnosed with lung cancer in February 2021 and was treated successfully at Memorial Sloan Kettering Cancer Center.

… Thursday, September 26, 2024 Sandra Lowe’s lung cancer lung cancer diagnosis came out of nowhere. She was 63, healthy and living an active life near Albany, New York, working full-time at a credit union, hiking the Adirondack Mountains with her husband, and visiting her two sons in Boston. When a routine

Esta es Sandra Lowe, a quien le diagnosticaron cáncer pulmonar en febrero de 2021 y fue tratada con éxito en el Memorial Sloan Kettering Cancer Center.

… Thursday, September 26, 2024 El diagnóstico de cáncer pulmonar cáncer pulmonar de Sandra Lowe surgió de repente. Tenía 63 años, era una persona saludable y llevaba una vida activa cerca de Albany, Nueva York. Trabajaba a tiempo completo en una cooperativa de crédito, caminaba por las montañas Adirondack

He was given a wrong diagnosis. A blood test changed his life.

… Wednesday, March 20, 2019 Summary A noninvasive genetic test known as liquid biopsy is helping doctors choose the best treatment for their patients based on the unique characteristics of their tumors. When 34-year-old Joey Laurore came to Memorial Sloan Kettering in 2017, he was looking for a second

The noninvasive approach could help scientists track the movements of an important cell type that can influence the outcome of cancer treatment.

… Thursday, November 2, 2017 Summary A new technique allows scientists to see macrophages in tumors by the way they concentrate iron. Macrophages, a type of immune cell, can influence how well a person fares on cancer treatment . The technique is noninvasive and could one day help doctors tailor treatments

Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.

… Wednesday, October 17, 2012 Summary Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer. Construction on the Mortimer B. Zuckerman Research Center – named in recognition of the $100

The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.

… Tuesday, January 5, 2021 The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma.  The drug , also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering

美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物也称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。

… Tuesday, January 5, 2021 美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物 也被称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。 Naxitamab 的临床试验由儿科肿瘤医生 Brian Kushner 和 MSK 斯隆儿科项目的神经母细胞瘤团队主导开展。 如今美国和全球的患者将更容易获得这种治疗。 神经母细胞瘤 是一种罕见的神经组织癌症，通常源于腹部。 其主要影响幼儿群体。 尽管过去这种疾病在几乎所有的高危病例中都是致命的，但在过去的二十年中，其前景得到了相当大的改善

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).

… Monday, April 29, 2024 MSK Clinical Trials for Patients with BCG-Naïve, BCG-Exposed, and BCG-Unresponsive Bladder Cancer Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

… Friday, October 25, 2013 Summary Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients. Despite tremendous advances in medical research in recent decades, the number of new treatments that

Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.

… Wednesday, February 8, 2012 Summary Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1. For the first time, Memorial Sloan Kettering investigators have revealed the three-dimensional shape of a protein called K2P1